Bilal Ahmed, MD
Endocrinology, Diabetes & Metabolism · Bismarck, NDNPI 1720025034
Payments from drug & device makers
What this record shows
This record is dominated by grants: $6,667 of the $6,973 with a category attached, or 95.6%. Medtronic accounts for 95.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $6,735 and has fallen 97.8% since, to $145 in 2025.
Across 14 payments — averaging $498.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Dexcom, Inc.$87
- Ipsen Biopharmaceuticals, Inc$44
- Amgen$35
- Corcept Therapeutics$29
- Novo Nordisk$28
- plus $68 from 3 others
What the payments were for
- Grants$6,66796%
- Food & beverage$3074%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $6,682 |
| Dexcom, Inc. | 4 | $87 |
| Ipsen Biopharmaceuticals, Inc | 1 | $44 |
| Amgen(2 entities) | 2 | $35 |
| Corcept Therapeutics | 1 | $29 |
| Novo Nordisk | 1 | $28 |
| Madrigal Pharmaceuticals | 1 | $28 |
| Tandem Diabetes Care, Inc. | 1 | $22 |
| Bayer | 1 | $18 |
How this compares
Too few endocrinology, diabetes & metabolism providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 20 | $35,771 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $21,545 |
| TrulicityDulaglutide | 13 | $14,868 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $11,950 |
| FarxigaDapagliflozin Propanediol | 13 | $8,580 |
| Novolog FlexpenInsulin Aspart | 14 | $4,241 |
| Levothyroxine Sodium | 224 | $3,400 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $3,238 |
| SynthroidLevothyroxine Sodium | 17 | $1,322 |
| Hydrocortisone | 39 | $1,307 |
| Liothyronine Sodium | 12 | $504 |
| Metformin Hcl | 28 | $309 |
| Methimazole | 20 | $221 |
| Atorvastatin Calcium | 12 | $151 |
| Rosuvastatin Calcium | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $28 | $35,77120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in North Dakotaon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Bismarck
- Rodhan KhthirBismarck$2K
- William ZaksGrand Forks$63K
- Mario RiveraFargo$1K
- Raul Ruiz EspondaFargo$523
- Soamsiri NiwattisaiwongFargo$383
- David NewmanFargo$134
- Niyutchai ChaithongdiFargo$36
- William NewmanFargo$28
- Bharat RamanFargo$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.